+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07553637

Randomized Double-Blind Trial of ALTO-207 Versus Placebo in Adults With Treatment-Resistant Depression

Led by Alto Neuroscience · Updated on 2026-10-26

178

Participants Needed

63

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying adults with treatment-resistant depression TRD to evaluate the effects of ALTO-207 compared with a placebo. This clinical trial aims to measure changes in depressive symptoms, particularly focusing on the Montgomery-sberg Depression Rating Scale MADRS scores over eight weeks. The study is randomized, double-blind, and placebo-controlled, conducted by Alto Neuroscience. Participants receive either ALTO-207 or a matching placebo twice daily BID during the treatment phase. The trial follows a parallel design, comparing the effects of the experimental drug to placebo over the course of the study. Throughout the trial, participants undergo assessments including changes in MADRS scores and clinician-administered Clinical Global Impression-Severity CGI-S scores. The primary outcome is the change from baseline in MADRS total score up to eight weeks. Secondary outcomes include response rates and CGI-S score changes. Safety and adherence are monitored, with a total participation period extending through the eight-week treatment phase and follow-up.

CONDITIONS

Brief Title

ALTO-207 in Adults With Treatment-resistant Depression (TRD)

Research Team

A

Alto Neuroscience

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here